alexa Approaches To Lead Generation - A Novel Molecular Target In Cancer Drug Discovery Development | 4855
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Approaches to lead generation - A novel molecular target in cancer drug discovery development

3rd World Congress on Biotechnology

P. Sarita Rajender, RajenderVadija,Thirupathi Mukkera and Uma Vuruputuri

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.S1.009

Abstract
Cell regulation is an essential mechanism in cell proliferation and has close relationship with carcinogenesis.The main focus in cancer research is on the formation, activation, inactivation,of Cyclin ? CDK(Cyclin Dependent Kinase) complex which forms the basis of cell regulation (1).Cyclin X1 is a new member of cyclin family which is located in nucleus, whose expression is induced by DNA damageand is transcriptionally activated by P53 tumour suppressor gene (2). CyclinX1 exerts a negative feedback regulation of P53 by regulating dephosphorylation of Mdm2, an Oncoprotein, by complexing with PP2A during nucleolar stress. (3,4). The main objective is to inhibit the binding of PP2A- Mdm2 complex (5)and with cyclin X1 which stabilizes P53 leading to cellcycle arrestor apoptosis. In the present work, the 3D model of cyclin X1is generated using homology modeling techniques and validation protocols. Active site prediction is carried out using various server tools and Schrodinger Suite, which allow envisaging the important pockets for putative receptor binding.(6,7,8).Further studies are aimed at designing new chemical entities which may be used as potent anti cancer therapeutic leads.
Biography
P. Sarita Rajender, DST ? Scientist at The Department of Chemistry, Nizam College, Osmania University since 2009 and has completedPh.D in Synthetic Organic Chemistry in the year 1996. She is a post-doctoral research fellow working on novel platforms for finding new leads in Cancer therapy. Patenting process is under progress for promising new lead molecules. Her field of research interest includes modeling of novel protein targets & identification of new chemical entities (NCE?s) using Computational Chemistry, Chemical-Biology and Software tools. She has mentored PG students in their dissertation workduring teaching tenure. She has actively involved in organizing seminars/ workshop for students. Dr. P. SaritaRajender published several research articles in reputed international journals and has presented papers at various International and National Conferences.
Relevant Topics
Top